JPMorgan Healthcare Conference Jan.11-14 San Francisco
We will be attending the 28th Annual JPMorgan Healthcare Conference in San Francisco and reporting on various companies and news on the Genetic Engineering News WEB site (www.genengnews.com). Although we will be attending presentations of companies in all sectors we will try to focus on the...
Volcano(VOLC) erupts 9% on Upgrade
Robert W. Baird and Co. analyst Lawrence Neibor upgraded four medtech stocks and helped get the "January effect" in full swing. Cyberonics (CYBX), Edwards Lifescience (EW), Thoratec (THOR) and Volcano (VOLC) were all upgraded to Outperform from Neutral. Volcano was up 9% to 19 in late afternoon...
Review of Biotech 2009 Fund and ETF Performance YTD
The Rayno LifeScience Biotech portfolio is up 11-15% YTD (15%+ with rebalancing as recommended). Among the big winners YTD are Regeneron (REGN) up 40%, Targacept (TRGT) up 880% and Inverness (IMA) up 72%. The portfolio included both biotech and diagnostic companies. We reviewed five other ETFs...
CompuGen(CGEN) deal sparks small cap biodiscovery stocks
CompuGen, an early stage drug and diagnostic discovery Company announced today a "Discovery on Demand" therapeutic peptide collaboration with Pfizer that focuses on three peptide drugs based upon CompuGen in silico discovery platforms. The predicted molecules will be synthesized and delivered...
Year End Biotech Rally on Schedule
Seasonality, deals and "healthcare reform lite" spur rally On November 18 we suggested some rebalancing in the Rayno Life Science Portfolio anticipating some year-end optimism.Today we got some help from licensing M&A and financing deals....